LuxCath LLC has announced that the company's technology was used for the first time in procedures to treat arrhythmia patients.
According to the medical technology company, the ablation procedures were performed in eleven arrhythmia patients including atrial fibrillation patients in Prague at Homolka Hospital.
‘LuxCath, an Allied Minds company, announced this week the promising results of their new technology to treat arrhythmia patients.’
The procedures were led by electrophysiologist Vivek Reddy, MD, Director of Arrhythmia Services at The Mount Sinai Hospital and the Mount Sinai Health System, and Petr Neuzil, MD, Director of Cardiology, Homolka Hospital.
The catheter-based technology can assess tissue contact, visualize lesions, and
detect lesion gaps in real-time. LuxCath's technology has market applications in all
arrhythmia ablation procedures and is being optimized for the treatment of Atrial
"In all eleven patients, the technology identified tissue contact and was easy to use. In a
wide variety of settings, we were able to assess and monitor ablation lesions as they were
being created. There were no complications," said Vivek Reddy, MD. "This is an
exciting step forward in the world of ablation. Based on our experience, the technology
platform is quite promising."
"We are thrilled with the performance of our optical tissue interrogation system for
contact and lesion progression assessment," said Dr. Omar Amirana, M.D., LuxCath
Chief Executive Officer and Senior Vice President at its parent company, Boston-based
Allied Minds. "Given the potential to positively impact all ablation procedures, we are
excited to advance the technology into the marketplace. This is an enormous milestone
for the company."